GlassScriptPhysician profile
Briana V Dahl
NPI 1477217487
$8,504.20
in general payments reported to CMS, 2019-2025
33 companies · $1,649 in 2025
The $1,649 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $208 · 2022: $1,378 · 2023: $2,727 · 2024: $2,542 · 2025: $1,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,822 · Education: $95.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,822.13 |
| Education | $95.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,331.48 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $1,010.08 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $623.30 | 2021-2024 | Xarelto |
| Edwards Lifesciences Corporation | $609.70 | 2023-2025 | Sapien 3 Ultra Resilia |
| Amgen INC. | $578.72 | 2022-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $488.73 | 2022-2025 | Jardiance |
| Boston Scientific Corporation | $452.12 | 2023-2025 | Watchman Flx, Bodyguardian, General - Therapies |
| Astrazeneca Pharmaceuticals LP | $427.79 | 2022-2025 | Farxiga, Wainua |
| E.R. Squibb & Sons, L.L.C. | $413.12 | 2022-2025 | Camzyos, Eliquis |
| Pfizer INC. | $395.62 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $328.83 | 2022-2025 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $275.12 | 2024 | Arcalyst |
| Silk Road Medical, INC. | $190.83 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Actelion Pharmaceuticals US, INC. | $173.57 | 2023-2024 | Uptravi, Opsumit |
| Scpharmaceuticals INC. | $148.72 | 2023-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $129.95 | 2022-2024 | Xience Skypoint |
| Abiomed | $121.76 | 2022-2023 | Impella |
| Medtronic, INC. | $120.29 | 2022-2023 | Venaseal |
| Cvrx, INC. | $114.27 | 2024 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $92.56 | 2022-2025 | |
| Amarin Pharma, INC. | $79.07 | 2021-2022 | |
| Inspire Medical Systems, INC. | $70.68 | 2024-2025 | Inspire |
| Philips North America LLC | $51.77 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Novo Nordisk INC | $43.86 | 2021-2023 | Wegovy |
| Kiniksa Pharmaceuticals, LTD. | $40.58 | 2023 | Arcalyst |
| Atricure, INC. | $35.47 | 2024 | |
| Alnylam Pharmaceuticals INC. | $34.66 | 2022 | |
| Esperion Therapeutics, INC. | $32.19 | 2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $26.41 | 2021-2022 | |
| Daiichi Sankyo INC. | $25.61 | 2023 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $17.30 | 2023 | Inpefa |
| Altathera Pharmaceuticals LLC | $15.05 | 2025 | Sotalol Hydrochloride |
| Vivaquant INC, Dba Rhythm Express | $4.99 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Briana Dahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.